{"title":"DoE-Optimized Minitabs: Fabricating a Promising Modified-Release Sprinkle Formulation.","authors":"Suman R Borsadiya, Dharmik M Mehta","doi":"10.2174/0126673878371241250705123006","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dysphagia is a challenging medical condition that significantly affects individuals' swallowing function, quality of life, and overall well-being, especially in geriatric and pediatric populations. Sprinkle formulations are emerging as a broadly accepted solution to this challenge. However, such formulations are quite challenging to formulate as modified-release delivery systems. The present study aims to resolve this issue by formulating modified-release minitabs of the model drug etoricoxib as a sprinkle formulation.</p><p><strong>Methods: </strong>A fabricated metal mold and punch system was used to manually manufacture minitabs with a diameter of 3.2 mm and a weight of approximately 22 mg. The formulation derived from trial batches was further optimized using a 3 × 2 complete factorial design, as implemented in Stat- Ease Design Expert 7.0 software (trial version). Independent factors HPMC K4M (X1) and K100M (X2) were optimized against dependent factors: Hardness (R1), Friability (R2), and Drug release at 2 hrs (R3), 4 hrs (R4), and 8 hrs (R5).</p><p><strong>Result: </strong>The derived, optimized formulation, based on a desirability function, sustained drug release for up to 8 hours and met all the acceptance criteria. The final dosage form was designed as a hard gelatin capsule filled with approximately 22 minitabs, in the form of a sprinkle formulation, to be sprinkled over soft foods for administration.</p><p><strong>Conclusion: </strong>As the formulation was designed using a model drug, further investigations with other drugs can also be done with relevant changes in the optimized formulation. In summary, it can also be utilized as a platform for developing modified-release sprinkle formulations of other drugs.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent advances in drug delivery and formulation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126673878371241250705123006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Dysphagia is a challenging medical condition that significantly affects individuals' swallowing function, quality of life, and overall well-being, especially in geriatric and pediatric populations. Sprinkle formulations are emerging as a broadly accepted solution to this challenge. However, such formulations are quite challenging to formulate as modified-release delivery systems. The present study aims to resolve this issue by formulating modified-release minitabs of the model drug etoricoxib as a sprinkle formulation.
Methods: A fabricated metal mold and punch system was used to manually manufacture minitabs with a diameter of 3.2 mm and a weight of approximately 22 mg. The formulation derived from trial batches was further optimized using a 3 × 2 complete factorial design, as implemented in Stat- Ease Design Expert 7.0 software (trial version). Independent factors HPMC K4M (X1) and K100M (X2) were optimized against dependent factors: Hardness (R1), Friability (R2), and Drug release at 2 hrs (R3), 4 hrs (R4), and 8 hrs (R5).
Result: The derived, optimized formulation, based on a desirability function, sustained drug release for up to 8 hours and met all the acceptance criteria. The final dosage form was designed as a hard gelatin capsule filled with approximately 22 minitabs, in the form of a sprinkle formulation, to be sprinkled over soft foods for administration.
Conclusion: As the formulation was designed using a model drug, further investigations with other drugs can also be done with relevant changes in the optimized formulation. In summary, it can also be utilized as a platform for developing modified-release sprinkle formulations of other drugs.